[Classification and risk stratification in hypertension Recommendations of the European Society for Hypertension (ESH)].
Zidek
Walter
W
Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V. Heidelberg.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005060:Europe; D005858:Germany; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000145:classification* / Q000150:complications / Q000188:drug therapy*; D008019:Life Style; D009765:Obesity / Q000150:complications; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014481:United States
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D002097:C-Reactive Protein